A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)
Authors:
Open Access
- 30 August 2011
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 18 (2) , 219-228
Abstract
Background: Open-label studies are not ideal for providing robust evidence for long-term maintenance of efficacy of medicines, especially where medicines provide symptom relief and where long-term use of a placebo may be problematic and not ethical. Objective: To evaluate the maintenance of efficacy of Sativex in subjects who have gained long-term symptomatic relief of spasticity in multiple sclerosis (MS), and to assess the impact of sudden medicine withdrawal. Methods: An enriched enrolment randomized withdrawal study design was used. Eligible subjects with ongoing benefit from Sativex for at least 12 weeks entered this 5-week placebo-controlled, parallel-group, randomized withdrawal study. Each subjects’ previous effective and tolerated dose was continued. Results: A total of 18 subjects per group were enrolled. Demographics showed a mean duration of MS of 16.4 years, spasticity 12.7 years, mean duration of Sativex use of 3.6 years (median 3.4 years) and a mean daily dose of 8.25 sprays. Primary outcome of time to treatment failure was significantly in favour of Sativex (p = 0.013). Secondary endpoints showed significant changes in the Carer and Subject’s Global Impression of Change scales in favour of Sativex. Conclusions: Maintenance of Sativex efficacy in long-term symptomatic improvement of spasticity to a group of subjects with MS has been confirmed using this study design.Keywords
This publication has 23 references indexed in Scilit:
- The Effect of Treatment Expectation on Drug Efficacy: Imaging the Analgesic Benefit of the Opioid RemifentanilScience Translational Medicine, 2011
- Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosisMultiple Sclerosis Journal, 2010
- Validity, reliability, and clinical importance of change in a 0—10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trialClinical Therapeutics, 2008
- Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosisEuropean Journal of Neurology, 2007
- Regional variations in the prevalence of multiple sclerosis in French farmersJournal of Neurology, Neurosurgery & Psychiatry, 2006
- The cannabis withdrawal syndromeCurrent Opinion in Psychiatry, 2006
- Biomechanical approaches applied to the lower and upper limb for the measurement of spasticity: A systematic review of the literatureDisability and Rehabilitation, 2005
- Neuropharmacology and therapeutic potential of cannabinoidsAddiction Biology, 2000
- Pharmacology of cannabinoid CB1 and CB2 receptorsPharmacology & Therapeutics, 1997
- High‐dose oral baclofenNeurology, 1991